bf/NASDAQ:KRYS_icon.jpeg

NASDAQ:KRYS

Krystal Biotech, Inc.

  • Stock

USD

Last Close

199.97

06/11 21:01

Market Cap

5.52B

Beta: 0.85

Volume Today

257.13K

Avg: 203.48K

PE Ratio

−105.15

PFCF: −26.48

    Description

    Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clini...Show More

    Earnings

    Earnings per Share (Estimate*)

    -2-1122017-03-312019-03-122021-03-012023-02-272024-08-05

    Revenue (Estimate*)

    20M40M60M80M100M2017-03-312019-03-122021-03-012023-02-272024-08-05

    *Estimate based on analyst consensus